Thank you to Becker's Healthcare for publishing our (AlloDirect, Inc.) perspective on ASC M&A trends for 2026. Three key areas shaping the market right now: 1. Supply Chain as a Valuation Driver 2. Customer Consolidation Driving Supplier Innovation 3. The Quiet Shift Away from GPO Sole-Sourcing The future belongs to platforms that control supply chain intelligence. AlloDirect is building that for allografts, and beyond. It’s a quick read, let me know your thoughts! https://lnkd.in/gvC-nAVQ BECKER'S ASC REVIEW SCA Health USPI, INC. AMSURG Ascension Ventures OrthoAlliance OrthoCarolina Lakeshore Bone & Joint Institute Indiana University Health Ambulatory Surgery Center Association (ASCA) Hospital for Special Surgery Your Surgery Store Surgery Partners, Inc Envision Healthcare Prime Healthcare Welsh, Carson, Anderson & Stowe TPG Warburg Pincus LLC Charlie DeCook The Resource Group, Spend Management Solutions Vizient, Inc MTF Biologics AlloSource® Vivex Biologics Berkeley Advanced Biomaterials AMSURG USPI, INC. OCA Ventures Elevate Ventures NLC Health Ventures Abundant Venture Partners Optum Ventures Michael Meneghini, MD Midwest Orthopaedics at Rush PELTO Health Partners
FYZICAL Therapy & Balance…•1K followers
1moInsightful perspective. Florida remains one of the most competitive ASC markets in the country, especially in MSK. The platforms that can integrate new sites quickly, align physician partners, and standardize KPIs across service lines are the ones positioned to lead the next phase of growth in 2026.